Anzeige
Mehr »
Freitag, 21.08.2026 - Börsentäglich über 12.000 News
Washington beschleunigt New Amalga: Die US-Regierung verändert die Grande-Portage-Story
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41G7H | ISIN: US8964386036 | Ticker-Symbol: TRB0
NASDAQ
20.08.26 | 21:57
10,550 US-Dollar
-4,18 % -0,460
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRINITY BIOTECH PLC ADR Chart 1 Jahr
5-Tage-Chart
TRINITY BIOTECH PLC ADR 5-Tage-Chart

Aktuelle News zur TRINITY BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TRINITY BIOTECH Aktie jetzt für 0€ handeln
14.08.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer5
14.08.Trinity Biotech plc: Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement599- Perceptive Advisors provides approximately $7.0 million of additional investment to further support strategic growth initiatives including CGM+, Trinovium and the Company's business transformation...
► Artikel lesen
22.07.Trinity Biotech inks partnership to pair CGM+ with drug delivery system5
22.07.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer1
22.07.Trinity Biotech announces 1-for-30 ADS reverse split; shares down2
22.07.Trinity Biotech partners with Latch Medical on metabolic health tech5
22.07.Trinity Biotech kooperiert mit Latch Medical bei Technologie für Stoffwechselgesundheit4
22.07.Trinity Biotech plans 1-for-30 reverse ADS split2
22.07.Trinity Biotech plc: Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology259- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop...
► Artikel lesen
22.07.Trinity Biotech plant Reverse-ADS-Split im Verhältnis 1:3013
22.07.Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change209DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the "Company") today announced that it plans to change the ratio of the American depositary shares ("ADSs") representing...
► Artikel lesen
02.07.Trinity Biotech reports positive clinical findings for next-gen CGM4
02.07.Trinity Biotech meldet Durchbruch: CGM+ Sensor erkennt Fehlalarme bei Glukosemessung im Schlaf15
02.07.Trinity Biotech CGM+ detects false low glucose alerts during sleep3
30.06.Trinity Biotech plc: Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling105- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by...
► Artikel lesen
29.06.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer1
29.06.Trinity Biotech plc: Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville256DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing...
► Artikel lesen
23.06.Trinity Biotech launches liquid cooling subsidiary Trinovium18
23.06.Trinity Biotech plc: Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market270- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance...
► Artikel lesen
18.06.Trinity Biotech meldet Aufträge für über 2 Millionen HIV-Tests und legt Q1-Zahlen vor7
Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1